Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135(16):1319–31.
2. Thompson LD, Wenig BM, Adair CF, Smith BC, Heffess CS. Langerhans cell histiocytosis of the thyroid: a series of seven cases and a review of the literature. Mod Pathol. 1996;9(2):145–9.
3. Morimoto A, Shioda Y, Imamura T, Kudo K, Kawaguchi H, Sakashita K, et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans cell histiocytosis study group-02 protocol study. Int J Hematol. 2016;104(1):99–109.
4. Kudo K, Toki T, Kanezaki R, Tanaka T, Kamio T, Sato T, et al. BRAF V600E-positive cells as molecular markers of bone marrow disease in pediatric Langerhans cell histiocytosis. Haematologica. 2022;107(7):1719–25. https://doi.org/10.3324/haematol.2021.279857.
5. Chakraborty R, Burke TM, Hampton OA, Zinn DJ, Lim KP, Abhyankar H, et al. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016;128(21):2533–7. https://doi.org/10.1182/blood-2016-08-733790.